An investigation into Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)’s technical aspects

The price of Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) closed at $0.78 in the last session, down -0.58% from day before closing price of $0.78. In other words, the price has decreased by -$0.0045 from its previous closing price. On the day, 2090495 shares were traded. RIGL stock price reached its highest trading level at $0.8000 during the session, while it also had its lowest trading level at $0.7272.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.



We take a closer look at RIGL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.20 and its Current Ratio is at 2.30.

Upgrades & Downgrades

On June 08, 2022, Piper Sandler Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $7 to $1.

Cantor Fitzgerald Downgraded its Overweight to Neutral on June 08, 2022, whereas the target price for the stock was revised from $6 to $1.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 09 when RODRIGUEZ RAUL R bought 1,000,000 shares for $0.69 per share. The transaction valued at 688,400 led to the insider holds 1,391,776 shares of the business.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 1.48.

Stock Price History:

Over the past 52 weeks, RIGL has reached a high of $3.52, while it has fallen to a 52-week low of $0.64. The 50-Day Moving Average of the stock is 0.9306, while the 200-Day Moving Average is calculated to be 1.7412.

Shares Statistics:

According to the various share statistics, RIGL traded on average about 2.85M shares per day over the past 3-months and 1.36M shares per day over the past 10 days. A total of 172.84M shares are outstanding, with a floating share count of 170.76M. Insiders hold about 1.00% of the company’s shares, while institutions hold 77.60% stake in the company. Shares short for RIGL as of Oct 13, 2022 were 7.17M with a Short Ratio of 5.96M, compared to 10.95M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 4.15% and a Short% of Float of 4.87%.

Earnings Estimates

The company has 7 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.13 for the current quarter, with a high estimate of -$0.12 and a low estimate of -$0.16, while EPS last year was -$0.12. The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.11 and low estimates of -$0.15.

Analysts are recommending an EPS of between -$0.47 and -$0.57 for the fiscal current year, implying an average EPS of -$0.51. EPS for the following year is -$0.3, with 7 analysts recommending between -$0.21 and -$0.44.

Revenue Estimates

According to 6 analysts, the current quarter’s revenue is expected to be $22.61M. It ranges from a high estimate of $24.52M to a low estimate of $21.1M. As of the current estimate, Rigel Pharmaceuticals Inc.’s year-ago sales were $23.56M, an estimated decrease of -4.00% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $22.96M, an increase of 12.50% over than the figure of -$4.00% in the same quarter last year. There is a high estimate of $26.11M for the next quarter, whereas the lowest estimate is $20.94M.

A total of 6 analysts have provided revenue estimates for RIGL’s current fiscal year. The highest revenue estimate was $97.18M, while the lowest revenue estimate was $89.3M, resulting in an average revenue estimate of $93.37M. In the same quarter a year ago, actual revenue was $149.24M, down -37.40% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $122.68M in the next fiscal year. The high estimate is $152.85M and the low estimate is $95.52M. The average revenue growth estimate for next year is up 31.40% from the average revenue estimate for this year.